Blue­bird bio adds a key process to pi­o­neer­ing gene ther­a­py as it ramps up a piv­otal PhI­II

Blue­bird bio be­lieves it has de­vel­oped a new process that will make a marked im­prove­ment in their pi­o­neer­ing gene ther­a­py pro­grams, promis­ing to de­liv­er a sig­nif­i­cant im­pact on pa­tient out­comes in a new­ly-launched piv­otal study for Lenti­Glo­bin.

Late last year, blue­bird bio ex­ecs were forced to ex­plain why the lat­est da­ta on Lenti­Glo­bin had proved dis­ap­point­ing in a small set of sick­le cell pa­tients be­ing test­ed. In­stead of the cure that blue­bird $BLUE was look­ing for, sev­er­al pa­tients ex­pe­ri­enced a less than op­ti­mal re­sponse in pro­duc­ing an­ti-sick­ling he­mo­glo­bin, which caused more than a few in­vestors in the com­pa­ny to do a dou­ble take on the com­pa­ny’s prospects.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER